Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets continue to slide
Fri, 8 Aug 11:30 am

After opening weak, the Indian Indices have remained below the dotted line in the morning session stocks. Barring stocks from IT sector all the sectoral indices are witnessing selling pressures.

The BSE-Sensex is trading down 300 points. The NSE-Nifty is trading down 95 points. The BSE Mid Cap index is trading down 1.78% and the BSE Small Cap index is trading down 1.88%. The rupee is trading at 61.41 to the US dollar.

Automobile stocks are trading in weak with Mahindra and Mahindra Ltd (M&M) and Escorts Ltd being the leading losers. As per the financial daily, Society of Indian Automobile Manufacturers (SIAM), has released data of automobile sales for the month of July. As per this data, the domestic passenger car sales grew by 5.04% YoY for the month July. The motorcycle sales were up by 6.17% YoY for the said period. The two-wheeler category witnessed growth of 13.73% YoY for the said month. The total sales of vehicles across the categories grew by 12% YoY during the month.

Indian pharma stocks are trading mixed with Ipca labs and Orchid chemicals being among the leading losers and Wockhardt Ltd and Indoco Remedies being the leading gainers in the pack. As per the financial daily, Dr Reddys Laboratories has filed paragraph IV on Copaxone 40mg/ml injectable. Copaxone is generically known as glatiramer acetetate and is indicated for multiple sclerosis. Reportedly, Teva will be soon filing the litigation on Dr Reddy's claiming infringement of the patents on copaxone. Dr Reddys has challenged patents the latest one expiring in 2030. Teva intends to file a lawsuit for patent infringement against Dr. Reddy's within the 45 day period provided under the Hatch-Waxman Act. The filing of the lawsuit will trigger a 30 month stay of FDA approval of Dr. Reddy's ANDA. Dr Reddy's is trading up by 0.58%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets continue to slide". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.